apremilast

Known as: Apremilastum, Aprémilast, N-{2-[(1S)-1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
BACKGROUND Apremilast works intracellularly to regulate inflammatory mediators. OBJECTIVE ESTEEM 1 evaluated efficacy/safety of… (More)
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND Apremilast, an oral phosphodiesterase 4 inhibitor, regulates immune responses associated with psoriasis. OBJECTIVES… (More)
Is this relevant?
Highly Cited
2014
Highly Cited
2014
OBJECTIVES Apremilast, an oral phosphodiesterase 4 inhibitor, regulates inflammatory mediators. Psoriatic Arthritis Long-term… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
Apremilast, an oral small molecule inhibitor of phosphodiesterase 4 (PDE4), is in development for chronic inflammatory disorders… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2012
Highly Cited
2012
OBJECTIVE To evaluate the efficacy and safety of apremilast, a novel, orally available small molecule that specifically targets… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Apremilast, a small-molecule inhibitor of phosphodiesterase 4, works intracellularly to modulate proinflammatory and… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Psoriasis and psoriatic arthritis are common clinical conditions that negatively impact health-related quality of life and are… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
Is this relevant?
2012
2012
OBJECTIVE To investigate the preliminary safety and efficacy of apremilast, an oral phosphodiesterase 4 inhibitor, for atopic… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 5
Is this relevant?
Highly Cited
2010
Highly Cited
2010
BACKGROUND AND PURPOSE Apremilast is an orally administered phosphodiesterase-4 inhibitor, currently in phase 2 clinical studies… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
INTRODUCTION Type 4 phosphodiesterases (PDE4) play an important role in immune cells through the hydrolysis of the second… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?